Market Overview

UPDATE: CRT Capital Initiates Coverage on Covidien plc. at Buy, Announces $82.00 PT

Related COV
With Actively Managed Funds, Be Wary Of Expense Ratios
US Stock Futures Drop Ahead Of GDP, Jobless Claims Data
IRS, Eh? Tim Hortons Deal Could Lower Burger King's Tax Bill (Fox Business)

CRT Capital initiated coverage of Covidien (NYSE: COV) with a Buy rating and $82 price target. Shagun Chadha, analyst at CRT, believes the company “has a full pipeline and a road map to tap into five potentially $1+ billion high growth markets each.”

Shares have moved in a straight line higher since the open, now up about 1.4 percent to $71.34.

Chadha said Covidien can “consistently deliver 4-6% revenue growth lead by: a) an improvement in revenue mix towards higher-growth segments and geographies, b) new products introductions, and c) an appetite for strategic acquisitions.”

The analyst credited “solid execution” to the company's superb operational leverage, which, in addition to a non-US tax structure, provides “access to more cash to return to shareholders than its large cap medical technology peers.”

Chadha's projection “calls for 9-13% EPS growth [through 2017] with leverage from its restructuring programs.”

Latest Ratings for COV

Jul 2014CitigroupMaintainsBuy
Jul 2014JefferiesMaintainsBuy
Jul 2014NeedhamDowngradesBuyHold

View More Analyst Ratings for COV
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target Initiation Analyst Ratings


Related Articles (COV)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters